PT3265487T - Anticorpos igg modificados que se ligam ao fator de crescimento transformador-beta1 com elevada afinidade, avidez e especificidade - Google Patents
Anticorpos igg modificados que se ligam ao fator de crescimento transformador-beta1 com elevada afinidade, avidez e especificidadeInfo
- Publication number
- PT3265487T PT3265487T PT167096668T PT16709666T PT3265487T PT 3265487 T PT3265487 T PT 3265487T PT 167096668 T PT167096668 T PT 167096668T PT 16709666 T PT16709666 T PT 16709666T PT 3265487 T PT3265487 T PT 3265487T
- Authority
- PT
- Portugal
- Prior art keywords
- beta1
- avidity
- specificity
- modified
- growth factor
- Prior art date
Links
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 title 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 title 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128149P | 2015-03-04 | 2015-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3265487T true PT3265487T (pt) | 2022-09-29 |
Family
ID=55524479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167096668T PT3265487T (pt) | 2015-03-04 | 2016-03-03 | Anticorpos igg modificados que se ligam ao fator de crescimento transformador-beta1 com elevada afinidade, avidez e especificidade |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11325970B2 (pt) |
| EP (2) | EP4163299A1 (pt) |
| JP (1) | JP6745275B2 (pt) |
| KR (2) | KR102560072B1 (pt) |
| CN (1) | CN107787329B (pt) |
| AR (1) | AR103840A1 (pt) |
| AU (1) | AU2016226098B2 (pt) |
| BR (1) | BR112017018678A2 (pt) |
| CA (1) | CA2978439A1 (pt) |
| DK (1) | DK3265487T3 (pt) |
| ES (1) | ES2927297T3 (pt) |
| HR (1) | HRP20221142T1 (pt) |
| HU (1) | HUE059644T2 (pt) |
| IL (1) | IL254239B2 (pt) |
| LT (1) | LT3265487T (pt) |
| MX (1) | MX2017011252A (pt) |
| PL (1) | PL3265487T3 (pt) |
| PT (1) | PT3265487T (pt) |
| RS (1) | RS63589B1 (pt) |
| RU (1) | RU2728858C2 (pt) |
| SG (2) | SG10201908019UA (pt) |
| SI (1) | SI3265487T1 (pt) |
| TW (1) | TWI733661B (pt) |
| WO (1) | WO2016141245A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| KR20180122397A (ko) | 2016-03-11 | 2018-11-12 | 스칼러 락, 인크. | TGFβ1-결합 이뮤노글로불린 및 그의 용도 |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| JP7384415B2 (ja) | 2018-05-10 | 2023-11-21 | ミラバイオロジクス株式会社 | 抗体の抗原結合領域を含み、生理活性ペプチドを融合する人工タンパク質 |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| EP1486560A3 (en) | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| WO2004098637A1 (en) | 2003-04-30 | 2004-11-18 | Genzyme Corporation | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| ES2527292T3 (es) | 2004-03-31 | 2015-01-22 | Genentech, Inc. | Anticuerpos anti-TGF-beta humanizados |
| CA2581787A1 (en) * | 2004-09-22 | 2006-04-06 | Genzyme Corporation | Use of tgf-b antagonists to limit nephrotoxicity of immunosuppressive agents |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| RS51845B (en) | 2005-04-22 | 2012-02-29 | Eli Lilly And Company | SPECIFIC TGF BETA 1 ANTIBODIES |
| AU2006330542B2 (en) | 2005-12-23 | 2012-05-24 | Eli Lilly And Company | TGF-beta binding compositions |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| CA2644663A1 (en) | 2006-03-23 | 2007-09-27 | Kirin Pharma Kabushiki Kaisha | Agonist antibody to human thrombopoietin receptor |
| DK2918288T3 (da) | 2006-10-03 | 2017-11-27 | Genzyme Corp | Anvendelse af TGF-beta-antagonister til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi |
| BRPI0913991A2 (pt) | 2008-07-02 | 2015-11-17 | Emergent Product Dev Seattle | imunoterápicos da il6 |
| US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| TWI803876B (zh) * | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| KR102577578B1 (ko) * | 2011-06-03 | 2023-09-11 | 조마 테크놀로지 리미티드 | Tgf-베타에 특이적인 항체 |
| US20140072581A1 (en) | 2012-07-23 | 2014-03-13 | Zymeworks Inc. | Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains |
| EP3415633B1 (en) | 2013-03-11 | 2020-10-28 | Genzyme Corporation | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
-
2016
- 2016-03-02 TW TW105106247A patent/TWI733661B/zh active
- 2016-03-03 CA CA2978439A patent/CA2978439A1/en active Pending
- 2016-03-03 PT PT167096668T patent/PT3265487T/pt unknown
- 2016-03-03 EP EP22180865.2A patent/EP4163299A1/en active Pending
- 2016-03-03 SG SG10201908019U patent/SG10201908019UA/en unknown
- 2016-03-03 WO PCT/US2016/020780 patent/WO2016141245A1/en active Application Filing
- 2016-03-03 US US15/555,500 patent/US11325970B2/en active Active
- 2016-03-03 RS RS20220886A patent/RS63589B1/sr unknown
- 2016-03-03 MX MX2017011252A patent/MX2017011252A/es unknown
- 2016-03-03 RU RU2017134043A patent/RU2728858C2/ru active
- 2016-03-03 KR KR1020177027372A patent/KR102560072B1/ko active IP Right Grant
- 2016-03-03 PL PL16709666.8T patent/PL3265487T3/pl unknown
- 2016-03-03 LT LTEPPCT/US2016/020780T patent/LT3265487T/lt unknown
- 2016-03-03 KR KR1020237024971A patent/KR20230116946A/ko active IP Right Grant
- 2016-03-03 HU HUE16709666A patent/HUE059644T2/hu unknown
- 2016-03-03 SI SI201631598T patent/SI3265487T1/sl unknown
- 2016-03-03 ES ES16709666T patent/ES2927297T3/es active Active
- 2016-03-03 DK DK16709666.8T patent/DK3265487T3/da active
- 2016-03-03 AU AU2016226098A patent/AU2016226098B2/en active Active
- 2016-03-03 EP EP16709666.8A patent/EP3265487B1/en active Active
- 2016-03-03 SG SG11201707109XA patent/SG11201707109XA/en unknown
- 2016-03-03 AR ARP160100560A patent/AR103840A1/es unknown
- 2016-03-03 CN CN201680025633.5A patent/CN107787329B/zh active Active
- 2016-03-03 JP JP2017546179A patent/JP6745275B2/ja active Active
- 2016-03-03 HR HRP20221142TT patent/HRP20221142T1/hr unknown
- 2016-03-03 BR BR112017018678A patent/BR112017018678A2/pt active Search and Examination
-
2017
- 2017-08-31 IL IL254239A patent/IL254239B2/en unknown
-
2022
- 2022-04-11 US US17/717,967 patent/US11834495B2/en active Active
-
2023
- 2023-10-23 US US18/492,150 patent/US20240117028A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254239A0 (en) | Modified antibodies that bind to transforming growth factor-beta-1 with high affinity, avidity and specificity | |
| IL264654B1 (en) | Anti-tigit antibodies, anti-pvrig antibodies and their combinations | |
| ZA201704117B (en) | Cd47 antibodies, methods, and uses | |
| IL304772A (en) | Antibodies, uses and methods | |
| IL258036A (en) | Optimized bispecific antibodies against class 3 determinants and their uses | |
| AU2016210068A1 (en) | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 | |
| EP3116544A4 (en) | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies | |
| EP3186279C0 (en) | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 | |
| WO2014144865A3 (en) | Anti-crth2 antibodies and their use | |
| EP3411069A4 (en) | HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF | |
| EP3200823A4 (en) | Multivalent meditopes, meditope-binding antibodies and uses thereof | |
| IL252430A0 (en) | Antibodies, uses and methods | |
| IL254238A0 (en) | ß1 transforming growth factor binding dimers with high affinity, avidity and specificity | |
| IL247590A0 (en) | Bispecific antibodies and their uses | |
| EP3185897A4 (en) | Antibody therapeutics that bind oprf and opri | |
| EP3592386A4 (en) | ANTI-C5 ANTIBODIES AND THEIR USES | |
| EP3209686A4 (en) | Monoclonal anti-gpc-1 antibodies and uses thereof | |
| EP3253789A4 (en) | Anti-salmonella antibodies and uses thereof | |
| EP3455260A4 (en) | ANTI-ERBB-2 ANTIBODIES AND USES THEREOF | |
| GB201713147D0 (en) | Antibodies, combinations comprising antibodies, biomarkers, uses and methods | |
| GB201618515D0 (en) | Combinations comprising antibodies, uses and methods | |
| GB201512223D0 (en) | Methods for the production and use of high specificity, high affinity antibodies |